Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 87c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 87c

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 4, 2021 4:06 PM EDT

To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide

In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration revenue recognized

Anticipated fourth quarter milestones include: topline sotrovimab intramuscular administration data, new hepatitis B data at AASLD and initial HIV vaccine immunology data

SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

The third quarter was both rewarding and... More